Lumican Antibody (1096907) [Unconjugated]

Western Blot shows lysates of human cartilage and human colon tissues. PVDF membrane was probed with 2 µg/ml of Rat Anti-Human Lumican Monoclonal Antibody (Catalog # MAB11706) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (Catalog # HAF005). A specific band was detected for Lumican at approximately 60-80 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

Lumican was detected in immersion fixed paraffin-embedded sections of human kidney using Rat Anti-Human Lumican Monoclonal Antibody (Catalog # MAB11706) at 5 µg/ml overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using the HRP-conjugated Anti-Rat IgG Secondary Antibody (Catalog # HAF005) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

• Reactivity: Hu
• Applications: WB, IHC
• Clone: 1096907
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated

Lumican Antibody (1096907) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line, NS0-derived human Lumican
  Gln19-Asn338
  Accession # P51884
• Specificity: Detects recombinant human Lumican protein in Direct ELISA.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 3-25 ug/mL
  • Western Blot 2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Reconstitution Instructions: Reconstitute lyophilized material at 0.2 mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Lumican Antibody (1096907) [Unconjugated]

• KSPG lumican
• LDC
• LUM
• lumican proteoglycan
• Lumican
• SLRR2D
• SLRR2DLDCKeratan sulfate proteoglycan lumican

Background

Lumican is a 40 kDa member of the family of small leucine-rich repeat proteoglycans (SLRPs) and the class II subfamily (1). Human Lumican is synthesized as a 338 amino acid (aa) precursor that contains an 18 aa signal sequence and a 320 aa mature chain (SwissProt #: P51884). The mature chain contains a negatively charged N-terminal domain containing sulfated tyrosine and disulfide bonds, 12 leucine-rich repeats (LRRs), four potential sites of N-linked glycosylation, and a carboxyl terminal domain containing two conserved cysteines (1). Mature human Lumican is 88%, 87%, and 70% aa identical to mature mouse, rat, and chick Lumican, respectively. SLRPs constitute an important fraction of noncollagenous extracellular matrix proteins (ECM) proteins (1, 2). Lumican is expressed in a variety of tissues, including skin, artery, lung, cornea, kidney, bone, aorta, and articular cartilage (1). Lumican’s role in vivo has been found using Lumican null mice. These mice have functional deficits including corneal opacity as well as skin and tendon fragility associated with disorganized and loosely packed collagen fibers
(1, 3-6). The abnormal connective tissue phenotype seen in the Lumican null mice shows the importance of the role of Lumican in collagen fibrillogenesis (1). In addition to the control of collagen fibril assembly, Lumican has been shown to play a role in the regulation of cell proliferation (7, 8), migration (8, 9), and adhesion (9). Lumican’s over-expression has been reported in carcinoid tumor, breast, colorectal, neuroendocrine, uterine cervical and pancreatic cancers (10).

1. Nikitovic, D. et al. (2008) IUBMB Life 60:818.
2. Blochberger, T.C. et al. (1992) J. Biol. Chem. 267:347.
3. Chakravarti, S. et al. (1998) J. Cell Biol. 141:1277.
4. Chakravarti, S. et al. (2000) Invest. Ophthalmol. Vis. Sci. 41:3365.
5. Jepsen, K.J. et al. (2002) J. Biol. Chem. 277:35532.
6. Chakravarti, S. et al. (2003) Invest. Ophthalmol. Vis. Sci. 44:2422.
7. Vuillermoz, B. et al. (2004) Exp. Cell Res. 296:294.
8. Nikitovic, D. et al. (2008) FEBS J. 275:350.
9. D’Onofrio, M.F. et al. (2008) Biochem. Biophys. Res. Commun. 365:266.
10. Ishiwata, T. et al. (2007) Oncol. Rep. 18:537.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P51884()